Ruxolitinib 1.5% Cream QD
Sponsors
Incyte Corporation, CAGE Bio Inc.
Conditions
Atopic DermatitisAtopic Dermatitis (AD)
Phase 2
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
CompletedNCT03011892
Start: 2017-01-09End: 2018-03-12Updated: 2021-04-09
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
CompletedNCT06923228
Start: 2025-04-21End: 2025-09-30Updated: 2026-04-01